Latest From David Wild
Mpox And Newfound ‘Punching Power’ Are Bringing Bavarian Nordic Closer To $1bn Target
Bavarian Nordic managed to change its financial story in 2022 when its smallpox vaccine, Jynneos, became a critical tool in the global response to the mpox pandemic. CEO Paul Chaplin speaks to In Vivo about what this year holds in store.
hVIVO's Andrew Catchpole On Human Challenge Studies, From COVID-19 To Malaria
hVIVO, a specialist contract research organization, performs human challenge trials, helping pharma companies develop vaccines with greater efficiency. Chief scientific officer Andrew Catchpole recently spoke with In Vivo about what it takes to perform an effective human challenge study, how they keep study participants safe, and how the company is helping address the ongoing scourge of malaria.
VC Playbook: Finding Early-Stage Financing When Money Is Scarce
Early-stage companies need to be more flexible on the financing terms they are willing to accept and in finding ways to gather evidence to support the impact of their products or services.
2023 Will Be A Year Of Partnerships And Acquisitions For Astellas
Astellas’ Mike Luther sees 2023 as a year of growing assets and creating partnerships. The global head of search and evaluation business development told In Vivo about the company's focus on gene and cell therapy and what he thinks makes for a successful business deal.
Nimbus CEO Talks $4bn Takeda Deal And Capital Cycles
In December 2022, Nimbus Inc. completed one of the largest single-asset deals in the history of biotech, selling their TYK2 inhibitor program NDI-034858 for an up-front payment of $4bn and up to $2bn in additional milestone payments. What was it like to close a deal of that magnitude? What’s next for Nimbus? The company‘s CEO, Jeb Keiper, reflected on these questions in a recent interview with In Vivo.
Slew Of Challenges Calls For Revised Biopharma Playbook
While not immune to the impact of a storm of macroeconomic pressures, pharma companies have pulled through before, and they’ll do it again. However, this time around, the economic, geopolitical and internal cost and revenue pressures are unique and weathering the near-term turbulence will call for smart investment strategies that not only focus on quality assets, but that update companies to take advantage of new digital opportunities.